In the context of Latin America, Chile is not a particularly large pharmaceutical and healthcare market as its population is relatively small ꦏand healthy in terms of incidence of communicable diseases. However, the country’s changing ...

Latin America was among the hardest-hit regions by the COVID-19 pandemic. The novel coronavirus entered the region at a bad time. The commodities boom at end of the 2000s combined with several local crises afterwardꦇs have hurt badly the 🌌public ...

In a Latin American context, Chile is not a particularly large pharmaceutical and healthcare market, since its&n🉐bsp;population is relatively small and healthy in terms of incidence of communicable diseases. However, the country’s changing ...

In the p🍎ast two decades, Latin America has embraced a universal health strategy, ba🎐sed on the principles of equity, solidarity and collective action. This strategy required steadily growing public expenditure on health in order to guarantee universal ...

In a Latin American context, Chile is not a particular♔ly large pharmaceutical and healthcare market, since its population is relatively small and healthy in terms of the incidence of communicable diseases. However, the country’s changing ...

Although the global pharma & healthcare sector is dominated by large multinational companies, mainly from the developed countries, Latin America has been quickly catching up in 📖building a domestic pharmaceutical production base and expanding the ...

In 2012-2017 Chile’s total health expenditure rose at a CAGR of 11.6%, driven by a solid increase of government spending on healthcare. In 2017, Chile allocated 8.1% of its GDP on healthcare, a figure thatꦓ is boun෴d to grow in the short term. ...

In 2015, Chile was the sixth largest pharmaceutical market in Latin America in terms of sales volume, with 278mn units sold, and the seventh biggest in terms of sales value, with USD 1.53bn, based on ex-factory prices (USD 2.32bn, based on retail ..꧋.